157. Sturge-Weber syndrome
8 clinical trials,   11 drugs   (DrugBank: 4 drugs),   5 drug target genes,   62 drug target pathways

Searched query = "Sturge-Weber syndrome", "Síndrome de Sturge-Weber"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04447846
(ClinicalTrials.gov)
October 14, 201910/10/2019Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber SyndromeNovel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II TrialSturge-Weber SyndromeDrug: CannabidiolAnne Comi, MDGW Pharmaceuticals Ltd.;Faneca 66 FoundationRecruiting3 Years50 YearsAll10Phase 2United States
2NCT03047980
(ClinicalTrials.gov)
January 20172/2/2017Trial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeTrial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeSturge-Weber SyndromeDrug: SirolimusAnne Comi, MDChildren's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting3 Years31 YearsAll10Phase 2;Phase 3United States
3NCT02332655
(ClinicalTrials.gov)
December 20145/1/2015Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber SyndromeCannabidiol Expanded Access Study in Medically Refractory Sturge-Weber SyndromeSturge-Weber SyndromeDrug: CannabidiolAnne Comi, MDGW Pharmaceuticals Ltd.;Faneca 66 FoundationActive, not recruiting1 Month45 YearsAll5Phase 1;Phase 2United States
4NCT01997255
(ClinicalTrials.gov)
April 201415/11/2013Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber SyndromeSturge Weber SyndromeDrug: EverolimusBaylor College of MedicineNovartis PharmaceuticalsWithdrawn2 Years18 YearsBoth0Phase 2United States
5NCT01533376
(ClinicalTrials.gov)
February 201211/2/2012Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical TimololTreatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical TimololSturge Weber Syndrome;Port-wine MarkDrug: Timolol;Drug: Preservative free artificial tear gel.Wills EyeUniversity of Medicine and Dentistry of New JerseyTerminated2 Years10 YearsAll3Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2010-024078-20-ES
(EUCTR)
11/05/201115/12/2010Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-WeberEnsayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber.
MedDRA version: 13;Level: PT;Classification code 10042265;Term: Síndrome de Sturge-Weber
Product Name: Rapamicina tópica al 1% y excipiente
INN or Proposed INN: crema de rapamicina al 1% y excipientes
Product Name: Crema placebo (excipiente)
INN or Proposed INN: Crema placebo (excipiente)
Instituto Científico y Tecnológico de NavarraNULLNot RecruitingFemale: yes
Male: yes
Spain
7NCT02080624
(ClinicalTrials.gov)
January 201118/4/2013Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber SyndromePhase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.Sturge- Weber SyndromeDrug: Drug: Topical RapamycinClinica Universidad de Navarra, Universidad de NavarraNULLCompleted16 Years65 YearsBoth23Phase 2Spain
8NCT00639730
(ClinicalTrials.gov)
May 200614/3/2008Use of the Atkins Diet for Children With Sturge Weber SyndromeUse of the Atkins Diet for Children With Sturge Weber SyndromeEpilepsy;Sturge Weber SyndromeDietary Supplement: modified Atkins dietJohns Hopkins UniversityVascular Birthmarks FoundationCompleted2 Years18 YearsBoth5Phase 1United States